Andy Hurley

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA.

Capgemini America, Inc. engages in the provision of software solutions. It offers outsourcing, consulting, and digital transformation. The company is headquartered in New York, NY.

Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Cytophage Technologies, Inc. is a Canadian biotech company that produces bacteriophages, which are organisms that infect and kill bacterial cells. Cytophage is based in Winnipeg, Canada, and Steven Theriault has been the CEO of the private company since 2017. The company's tailor-made bacteriophages are inexpensive, quick to produce, harmless to humans and animals, better for the environment, and highly effective against exposed bacteria. The company is working on a phage nasal spray that goes directly to the area where the SARS-CoV-2 virus infects the body, the mucosal membranes in the nose and throat, to promote the production of antibodies through an adaptive immune response, giving protection from infection. Cytophage's bacteriophages have countless applications in food safety, animal health, and human health, and can be used for the decontamination of hospital surfaces and counters, tools and instruments, beds and curtains, and anywhere else bacterial contamination is a concern.